Siloam Biosciences, Inc.

Siloam focuses on developing next generation of in-vitro diagnostic systems using its ultra-low volume, cost-effective, and easy-to-use for immunoassay Optimiser™ microfluidic technology.

Over 70 assays have been developed on the Optimiser™ platform, proving its robustness and universal nature.

The Optimiser™ platform is commercially offered as Optimiser™ Plus and OptiMax® microplates for existing, standard robotic automation, and as manual Optimiser™ Plus plates. The company also has developed TROVA®, a single-patient desktop system for use at point of care. Siloam is also developing a multipatient, multiplexed automated desktop system under a contract with the National Cancer Institute.

Currently, the company is investigating strategic alternatives for its businesses.

Company’s Keywords:

invitro diagnostics, diagnostics, imunoassay, ivd, life sciences, pointofcare testing, cancer, reference laboratory, microfluidics